Development asset linked to Enliven Therapeutics in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
pharma · Solid Tumors, Colorectal Cancer and Breast Cancer · HER2 Mutant Non-small Cell Lung Cancer · ELVN
Enliven Therapeutics
Enliven Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boulder, USA HQ
2019 Founded
75 Employees
Public company Type
ELVN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2019
- Employees
- 75
- Programs
- 6
- Drugs
- 13
- Patents
- 5
Enliven Therapeutics pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Enliven Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Enliven Therapeutics in public FDA and regional records.
-
Development asset linked to Enliven Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Enliven Therapeutics in public FDA and regional records.
-
Development asset linked to Enliven Therapeutics in public FDA and regional records.
-
Development asset linked to Enliven Therapeutics in public FDA and regional records.
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
Development asset linked to Enliven Therapeutics in public FDA and regional records.